◼ Archived
Business
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
Telix's $2.35 billion merger with ITM signals a bold move into radiopharmaceuticals, drawing analyst optimism.
Itm
2 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA has issued a complete response letter rejecting ITM's radiopharmaceutical therapy ITM-11, a drug positioned to compete with Novartis treatments.